Tag: PP Defence Therapeutics

Defence Therapeutics Inc. (CSE: DTC, OTCQB: DTCFF, FSE: DTC) is pleased to announce that Dr Maxime Parisotto has joined the Company as Chief Scientific Officer, Director of Science and Business Development.

Dr Maxime Parisotto is a seasoned biochemist with over 20 years of experience spanning academic research, drug development, and innovation.

He holds a PhD in biochemistry focused on breast cancer and metabolism and has held postdoctoral fellowships at prestigious institutions, including the IGBMC in Strasbourg, France, and the Université de Montréal.

Dr Parisotto’s track record as a leader

As Senior Analyst, he contributed to significant investment decisions at adMare Bioinnovations. He also holds a graduate certificate in life science entrepreneurship development from Concordia University and will graduate with an MBA from Sherbrooke University in April 2025.

Dr Parisotto has a robust track record of leadership, including managing multidisciplinary teams and contributing to high-impact scientific publications. Before joining adMare, he led research initiatives in cancer biology and stem cells at institutions such as the IRCM and Université de Montréal.

He is an active member of the Canadian biotech ecosystem, with an extensive professional network of contacts and regular participation in national and international conferences.

His research and business interests focus on advancing drug development from discovery to clinical stages and fostering collaborations between academia, industry, and investors to drive innovation in biopharmaceuticals. His scientific expertise is mainly in oncology, protein biochemistry, cell metabolism, and stem cell biology.

Support for the new appointment

“I am honoured and excited to join Defence Therapeutics as CSO and Director of Science & Business Development. I strongly believe that Defence’s proprietary Accum® technology platform has a great potential for the development of targeted therapies that will make a difference for the patients,” said Dr Maxime Parisotto.

Sébastien Plouffe, President, CEO and Founder of Defence Therapeutics, added: “We are proud to welcome Dr Maxime Parisotto as he is an accomplished and strong scientist with a mission to focus on the scientific programmes that will increase the value of Defence Therapeutics.

“His business knowledge is an important aspect that will guide and inspire the Company’s growth and development for the benefit of Defence’s shareholders.”

The company has granted 100,000 incentive stock options to Dr Parisotto in accordance with the terms and conditions of Defence’s stock option plan.

Each stock option vests immediately and is exercisable at a price of 60 cents per share for a period of three years from the grant date.

Defence would like to mention that Dr Moutih Rafei is no longer with the Company. The Company would like to thank Dr Rafei for his contributions.

Defence Therapeutics Inc., a Canadian biopharmaceutical company specialising in radiopharmaceuticals, antibody-drug conjugates (ADC), and immune-oncology vaccines, has announced that Dr Svetlana Selivanova has joined its board of directors, effective immediately.

Dr Selivanova brings over 20 years of expertise in radiopharmaceutical development, spanning from early-stage research to clinical trials. She holds a Master of Science in chemistry and a PhD in radiopharmaceutical chemistry and radiobiology.

Dr Selivanova is currently the Section Head for Radiochemistry and Medical Applications at Canadian Nuclear Laboratories (CNL) and serves as an adjunct professor at the Faculty of Pharmacy, Université Laval.

Before her role at CNL, she held senior research and management positions at CHU de Quebec-Université Laval, Sherbrooke University Hospital, and the Center for Radiopharmaceutical Sciences at ETH Zurich in Switzerland.

Professional associations and international expertise

An active contributor to her field, Dr Selivanova serves as an Executive Member of the Canadian Association of Radiopharmaceutical Scientists, President of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Radiopharmaceutical Sciences Council, and a member of the SNMMI Committee on Radiopharmaceuticals.

Internationally, she provides expert consultation to the International Atomic Energy Agency (IAEA) and the European Research Council. Her research interests include the development and clinical translation of novel radiopharmaceuticals, as well as nuclear imaging to explore biochemical pathways in vivo.

Among Dr Selivanova’s significant contributions is her role in the development of technetium-99m production using cyclotron technology, as well as her work on investigational radiopharmaceuticals for prostate cancer targeting the prostate-specific membrane antigen.

“We are proud to have Dr Svetlana Selivanova joining our board of directors,” commented Sébastien Plouffe, President, CEO, and Founder of Defence Therapeutics.

“She is a very strong addition to our company. Defence’s strategy is to develop radio-immuno-conjugates using our Accum^® platform. Dr Selivanova has extensive knowledge and experience in this field and will strengthen and accelerate our radiopharmaceuticals programmes.”

Dr Selivanova’s enthusiasm for Defence Therapeutics’ future

Dr Selivanova expressed her excitement in joining Defence Therapeutics, stating: “I am honoured to join Defence Therapeutics board of directors. I believe that Defence’s Accum^® technology platform has great potential for the development of targeted radiopharmaceutical therapies.”

In alignment with Defence’s stock option plan, the company has granted Dr Selivanova 100,000 incentive stock options. Each option vests immediately and is exercisable at 60 cents per share, with a three-year term from the grant date.

Defence Therapeutics also announced that Dr Raimar Lobenberg will be stepping down from the board. The company extends its gratitude to Dr Lobenberg for his valuable contributions to the board.